Cancers · 2022 · 20 citations · 37 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyMolecular Classification Of TumorsMolecular Tumor ProfilingTumor AntigensTumor ImmunopathologyTumor-infiltrating LymphocytesCd4+ Tumor-infiltrating LymphocytesCd8+ Tumor-infiltrating LymphocytesDiagnostic ImmunohistochemistryImmunohistochemistry AssaysMutationT Helper CellsTumor Genomic ProfilingTumor Immunogenomics
Angiosarcomas (AS) are extremely rare and aggressive vascular malignancies subdivided in de novo primary AS (pAS) and secondary AS (sAS). We hypothesize that the combination of immunological and genomic profiles significantly differs between primary and secondary AS, with potential impact on treatment strategies and a role for immunotherapy. Tumor-infiltrating lymphocytes were analyzed using multiplex immunohistochemistry from 79 pAS and 178 sAS. Median cell density was significantly higher in sAS for CD3+ T-cells (p < 0.001), CD8+ cytotoxic T-cells (p = 0.033), CD4+ T-helper cells (p < 0.001) and FoxP3+ T-regulatory cells (p < 0.001). CD20+ B-cell density was comparable (p = 0.417). Comprehensive genomic profiling was performed in 25 pAS and 25 sAS. A (likely) pathogenic mutation was detected in 80% of pAS vs. 88% of sAS (p = 0.702). Amplifications were found in 15% of pAS vs. 84% of sAS (p < 0.001). DNA damage response (DDR) pathway mutations (p = 0.021) and MYC amplifications (p < 0.001) were predominantly seen in sAS. In conclusion we observed a clear and clinical relevant distinction in immune infiltration and genomic profiles between pAS and sAS. The T-cell infiltrated tumor microenvironment and frequent DDR gene mutations, especially in sAS, warrant clinical trials with immunotherapy.
37
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John Tate, Sally Bamford, Harry Jubb et al. · Nucleic Acids Research · 2018 · 5.3K citations · Full text
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari et al. · Nature Genetics · 2019 · 4.4K citations · Full text
Medicine, Cancer Biology, Oncology +14
The repertoire of mutational signatures in human cancer
Mi Ni Huang, Alvin Wei Tian Ng, Arnoud Boot et al. · Nature · 2020 · 3.7K citations · Full text
Life Sciences, Genetics, Oncology +14
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Thierry André, Kai‐Keen Shiu, Tae Won Kim et al. · New England Journal of Medicine · 2020 · 3K citations · Full text
Medicine, Oncology, Pharmacology +17
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow, Jason Chesney, Anna C. Pavlick et al. · New England Journal of Medicine · 2015 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17